Does LORLATINIB Cause Neoplasm progression? 633 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 633 reports of Neoplasm progression have been filed in association with LORLATINIB (Lorbrena). This represents 11.5% of all adverse event reports for LORLATINIB.
633
Reports of Neoplasm progression with LORLATINIB
11.5%
of all LORLATINIB reports
278
Deaths
155
Hospitalizations
How Dangerous Is Neoplasm progression From LORLATINIB?
Of the 633 reports, 278 (43.9%) resulted in death, 155 (24.5%) required hospitalization, and 17 (2.7%) were considered life-threatening.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LORLATINIB. However, 633 reports have been filed with the FAERS database.
What Other Side Effects Does LORLATINIB Cause?
Death (1,050)
Off label use (394)
Weight increased (306)
Hallucination (290)
Blood cholesterol increased (281)
Dyspnoea (223)
Oedema peripheral (198)
Oedema (195)
Fatigue (188)
Peripheral swelling (164)
What Other Drugs Cause Neoplasm progression?
PALBOCICLIB (10,885)
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
Which LORLATINIB Alternatives Have Lower Neoplasm progression Risk?
LORLATINIB vs LORMETAZEPAM
LORLATINIB vs LORNOXICAM
LORLATINIB vs LOSARTAN
LORLATINIB vs LOSARTAN\LOSARTAN
LORLATINIB vs LOTEPREDNOL ETABONATE